Choi Byungjin, Jang Jong Hwan, Son Minkook, Lee Min Sung, Jo Yong Yeon, Jeon Ja Young, Jin Uram, Soh Moonseung, Park Rae Woong, Kwon Joon Myoung
Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Republic of Korea.
Department of Medical Research, Medical AI Co., Seoul, Republic of Korea.
Eur Heart J Digit Health. 2022 Apr 20;3(2):255-264. doi: 10.1093/ehjdh/ztac013. eCollection 2022 Jun.
Although overt hyperthyroidism adversely affects a patient's prognosis, thyroid function tests (TFTs) are not routinely conducted. Furthermore, vague symptoms of hyperthyroidism often lead to hyperthyroidism being overlooked. An electrocardiogram (ECG) is a commonly used screening test, and the association between thyroid function and ECG is well known. However, it is difficult for clinicians to detect hyperthyroidism through subtle ECG changes. For early detection of hyperthyroidism, we aimed to develop and validate an electrocardiographic biomarker based on a deep learning model (DLM) for detecting hyperthyroidism.
This multicentre retrospective cohort study included patients who underwent ECG and TFTs within 24 h. For model development and internal validation, we obtained 174 331 ECGs from 113 194 patients. We extracted 48 648 ECGs from 33 478 patients from another hospital for external validation. Using 500 Hz raw ECG, we developed a DLM with 12-lead, 6-lead (limb leads, precordial leads), and single-lead (lead I) ECGs to detect overt hyperthyroidism. We calculated the model's performance on the internal and external validation sets using the area under the receiver operating characteristic curve (AUC). The AUC of the DLM using a 12-lead ECG was 0.926 (0.913-0.94) for internal validation and 0.883(0.855-0.911) for external validation. The AUC of DLMs using six and a single-lead were in the range of 0.889-0.906 for internal validation and 0.847-0.882 for external validation.
We developed a DLM using ECG for non-invasive screening of overt hyperthyroidism. We expect this model to contribute to the early diagnosis of diseases and improve patient prognosis.
尽管显性甲状腺功能亢进会对患者的预后产生不利影响,但甲状腺功能检查(TFTs)并非常规进行。此外,甲状腺功能亢进的模糊症状常常导致该病被忽视。心电图(ECG)是一种常用的筛查测试,甲状腺功能与心电图之间的关联已广为人知。然而,临床医生很难通过细微的心电图变化来检测甲状腺功能亢进。为了早期发现甲状腺功能亢进,我们旨在开发并验证一种基于深度学习模型(DLM)的心电图生物标志物,用于检测甲状腺功能亢进。
这项多中心回顾性队列研究纳入了在24小时内接受心电图和TFTs检查的患者。为了进行模型开发和内部验证,我们从113194名患者中获取了174331份心电图。我们从另一家医院的33478名患者中提取了48648份心电图用于外部验证。使用500Hz的原始心电图,我们开发了一种DLM,分别利用12导联、6导联(肢体导联、胸前导联)和单导联(I导联)心电图来检测显性甲状腺功能亢进。我们使用受试者操作特征曲线(AUC)下面积来计算该模型在内部和外部验证集上的性能。使用12导联心电图的DLM在内部验证中的AUC为0.926(0.913 - 0.94),在外部验证中的AUC为0.883(0.855 - 0.911)。使用6导联和单导联的DLM在内部验证中的AUC范围为0.889 - 0.906,在外部验证中的AUC范围为0.847 - 0.882。
我们开发了一种利用心电图进行显性甲状腺功能亢进无创筛查的DLM。我们期望该模型有助于疾病的早期诊断并改善患者预后。